Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-32.05% $0.0282
America/New_York / 20 okt 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3.14 mill |
EPS: | -0.710 |
P/E: | -0.0397 |
Earnings Date: | Nov 07, 2023 |
SharesOutstanding: | 111.41 mill |
Avg Daily Volume: | 24.42 mill |
RATING 2023-11-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0397 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.0397 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ -0.0184 - 0.0276 ( +/- 500.00%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-19 | Harsaul Foundation | Sell | 9 363 760 | Ordinary Shares |
2023-10-20 | Harsaul Foundation | Sell | 4 758 899 | Ordinary Shares |
2023-10-19 | Altchem Ltd | Sell | 9 363 760 | Ordinary Shares |
2023-10-20 | Altchem Ltd | Sell | 4 758 899 | Ordinary Shares |
2023-10-18 | Harsaul Foundation | Sell | 3 421 537 | Ordinary Shares |
INSIDER POWER |
---|
-77.26 |
Last 95 transactions |
Buy: 43 304 967 | Sell: 77 056 281 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0282 (-32.05% ) |
Volume | 63.96 mill |
Avg. Vol. | 24.42 mill |
% of Avg. Vol | 261.97 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.